SAN FRANCISCO, California. (August 22, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Stephen Sundlof, DVM, PhD, former Director of Center for Veterinary Medicine at the U.S. Food and Drug Administration, as its Senior Vice President of Regulatory Affairs.
CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis.
SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol concurrence negotiated with the FDA and, if positive, is expected to lead to the approval of CereKin™ by 2015.
- Kindred Biosciences Added to the Russell 2000 IndexJune 15, 2017 - 12:32 am
- Kindred Biosciences to Present Data from Six Studies at the 2017 American College of Veterinary Internal Medicine ConferenceMay 30, 2017 - 9:01 am
- Kindred Biosciences to Present at 7th Annual LD Micro InvitationalMay 24, 2017 - 9:04 am